Literature DB >> 962360

Treatment of dermatomyositis in childhood.

V Dubowitz.   

Abstract

Analysis of the response to corticosteroid therapy in a personal series of 8 consecutive cases of dermatomyositis in childhood shows that there are advantages in a moderate dosage, short-term treatment schedule, with gradual tapering of the dosage as soon as there is clinical improvement without waiting for full remission, and in trying to stop steroid therapy within six months rather than following the more prolonged regimen currently still in vogue. Clinical response is a more reliable guide to progress than serum enzyme levels. Review of published reports suggests that overtreatment with corticosteroids may be a factor in chronicity of the disease and failure of adequate long-term response.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 962360      PMCID: PMC1546029          DOI: 10.1136/adc.51.7.494

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  20 in total

Review 1.  DERMATOMYOSITIS.

Authors:  S BITNUM; C W DAESCHNER; L B TRAVIS; W F DODGE; H C HOPPS
Journal:  J Pediatr       Date:  1964-01       Impact factor: 4.406

2.  DERMATOMYOSITIS AND FOCAL SCLERODERMA.

Authors:  C D COOK; F S ROSEN; B Q BANKER
Journal:  Pediatr Clin North Am       Date:  1963-11       Impact factor: 3.278

3.  Calcinosis in dermatomyositis; observations on course of disease in children and adults.

Authors:  S A MULLER; R K WINKELMANN; L A BRUNSTING
Journal:  AMA Arch Derm       Date:  1959-06

4.  Dermatomyositis; report of 26 cases in children with a discussion of endocrine therapy in 13.

Authors:  R J WEDGWOOD; C D COOK; J COHEN
Journal:  Pediatrics       Date:  1953-10       Impact factor: 7.124

5.  Treatment of polymyositis with immunosuppressive drugs.

Authors:  D C Haas
Journal:  Neurology       Date:  1973-01       Impact factor: 9.910

6.  Cell-mediated cytotoxicity to muscle in polymyositis. Effect of immunosuppression.

Authors:  R L Dawkins; F L Mastaglia
Journal:  N Engl J Med       Date:  1973-03-01       Impact factor: 91.245

7.  Cell-mediated immunity in polymyositis. Creatine phosphokinase release from muscle cultures.

Authors:  D C Haas; B G Arnason
Journal:  Arch Neurol       Date:  1974-09

8.  Prognosis in childhood dermatomyositis.

Authors:  D B Sullivan; J T Cassidy; R E Petty; A Burt
Journal:  J Pediatr       Date:  1972-04       Impact factor: 4.406

9.  Evaluation of laboratory tests in diagnosis and management of polymyositis.

Authors:  P J Vignos; J Goldwyn
Journal:  Am J Med Sci       Date:  1972-04       Impact factor: 2.378

10.  Juvenile dermatomyositis.

Authors:  R H Hill; W S Wood
Journal:  Can Med Assoc J       Date:  1970-11-21       Impact factor: 8.262

View more
  6 in total

Review 1.  Long-term outcomes in juvenile dermatomyositis: how did we get here and where are we going?

Authors:  Adam Huber; Brian M Feldman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

2.  Drug treatment of juvenile dermatomyositis.

Authors:  G Miller; J Z Heckmatt; V Dubowitz
Journal:  Arch Dis Child       Date:  1983-06       Impact factor: 3.791

3.  Intravenous immunoglobulin in juvenile dermatomyositis--four year review of nine cases.

Authors:  A Sansome; V Dubowitz
Journal:  Arch Dis Child       Date:  1995-01       Impact factor: 3.791

4.  Dermatomyositis: observations on the use of immunosuppressive therapy and review of literature. Cairo--Glasgow study group.

Authors:  A El-Ghobarey; G Balint; K de Ceulaer; W C Dick; W W Buchanan; T Hadidi; T A Hassan
Journal:  Postgrad Med J       Date:  1978-08       Impact factor: 2.401

5.  Prognosis and treatment of polymyositis with particular reference to steroid resistant patients.

Authors:  M Yoshioka; T Okuno; H Mikawa
Journal:  Arch Dis Child       Date:  1985-03       Impact factor: 3.791

6.  Juvenile dermatomyositis: a review.

Authors:  P Malleson
Journal:  J R Soc Med       Date:  1982-01       Impact factor: 18.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.